Showing 3631-3640 of 19355 results for "".
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
https://reachmd.com/programs/cme/when-blockers-fall-short-in-ohcm-time-for-a-new-approach/54838/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Guideline Updates Redefining Squamous Cell Carcinoma of the Anal Canal Care
https://reachmd.com/programs/project-oncology/guideline-updates-anal-canal-scc-care/54277/Given the latest updates to the NCCN® Clinical Practice Guidelines, the treatment of advanced squamous cell carcinoma of the anal canal is rapidly evolving—most notably with the introduction of immunotherapy in the first-line setting. Joining Dr. Charles Turck to break down the evidence behind theseDecoding the Data: Early Biologic Use and Psoriatic Arthritis
https://reachmd.com/programs/living-rheum/early-biologic-use-psoriatic-arthritis/51051/Can treating psoriasis early with biologics help prevent psoriatic arthritis? The data’s promising—but it’s complicated. Join Dr. Laura Coates as she unpacks the latest research, explaining how early intervention may influence outcomes and what real-world challenges come with interpreting observatioCan FOI Help Differentiate Psoriatic Arthritis from Erosive Hand Osteoarthritis?
https://reachmd.com/programs/Audioabstracts/foi-differentiate-psoriatic-arthritis-from-erosive-hand-osteoarthritis/51046/Distinguishing psoriatic arthritis from erosive hand osteoarthritis isn’t always straightforward—but a new imaging approach may help. Tune in to hear Ryan Quigley discuss a recent study assessing fluorescence optical imaging (FOI) and its potential to improve diagnostic accuracy in this challengingStratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
https://reachmd.com/programs/project-oncology/stratifying-advanced-endometrial-cancer-real-world-outcomes-by-molecular-subtype/35509/A recent study published in the International Journal of Gynecological Cancer found that molecular subtype was a significant predictor of time-to-recurrence and cancer-specific survival in advanced endometrial cancer. Dive into the data and explore implications for tailoring patient care.Prognostic Tools in the Management of ADPKD
https://reachmd.com/programs/cme/prognostic-tools-in-the-management-of-adpkd/13877/This Expert Exchange webcast is designed to help improve clinicians’ ability to utilize prognostic tools to monitor disease progression and implement appropriate treatment strategies in patients with ADPKD. This activity is not available for continuing educManagement of ADPKD
https://reachmd.com/programs/cme/management-of-adpkd/13878/This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD. This activity is not available for continuing education credit.Cracking the Code of Obstruction: Unmet Needs in oHCM
https://reachmd.com/programs/cme/cracking-the-code-of-obstruction-unmet-needs-in-ohcm/54837/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.CKD-aP: Beyond the Surface
https://reachmd.com/programs/cme/ckd-ap-beyond-the-surface/36294/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
https://reachmd.com/programs/cme/shifting-the-script-personalizing-overactive-bladder-treatment-in-complex-patients/54125/Examine strategies to personalize overactive bladder management, including in patients with BPH, with attention to β₃-agonists and APP-led care pathways.